2023
Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution
Santinelli E, Pascale M, Xie Z, Badar T, Stahl M, Bewersdorf J, Gurnari C, Zeidan A. Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution. Blood Reviews 2023, 62: 101130. PMID: 37679263, DOI: 10.1016/j.blre.2023.101130.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaMyeloid malignanciesLeukemia cell survivalBcl-2 signalingPro-apoptotic agentsClinical studiesMyeloid leukemiaMyeloid neoplasmsTherapeutic revolutionMolecular alterationsMyeloid neoplasiaTherapeutic landscapeSpecific drugsApoptosis dysregulationSynergistic efficacyNew drugsMechanism of apoptosisDrugsMalignancyCombination strategiesCell survivalAttractive targetApoptotic pathwayTreatmentApoptosis
2016
Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities
Stahl M, Kim TK, Zeidan AM. Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. World Journal Of Stem Cells 2016, 8: 316-331. PMID: 27822339, PMCID: PMC5080639, DOI: 10.4252/wjsc.v8.i10.316.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsLeukemia stem cellsNormal hematopoietic stem cellsHematopoietic stem cellsAcute myeloid leukemia stem cellsMyeloid leukemia stem cellsStem cellsAcute myeloid leukemiaMultitude of drugsNovel therapeutic agentsCancer stem cellsClinical trialsMyeloid leukemiaTherapeutic windowSelf-renewal pathwaysXenograft modelClinical developmentTherapeutic opportunitiesRational targetTherapeutic agentsLSC biologyAcceptable therapeutic windowDrugsCellsFunctional studiesLeukemia